Targeted Therapies in Triple-Negative Breast Cancer

Breast Care

Volumn 10, Issue 3, 2015, Pages 159-166

  Marmé, Frederik ^a   Schneeweiss, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bevacizumab; Immune checkpoint inhibitors; PARP inhibitors; Subtypes; Targeted therapy; Triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84937822565     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000433622     Document Type: Review

References (72)

1. von Minckwitz G, Untch M, Nüesch E, et al.: Impact of treatment characteristics on response of different breast cancer phenotypes: Pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-156.
2. Bauer KR, Brown M, Cress RD, et al.: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 2007; 109: 1721-1728.
3. Dent R, Trudeau M, Pritchard KI, et al.: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
4. Gluz O, Liedtke C, Gottschalk N, et al.: Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-1927.
5. Bosch A, Eroles P, Zaragoza R, et al.: Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010; 36: 206-215.
6. de Ruijter TC, Veeck J, de Hoon JP, et al.: Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011; 137: 183-192.
7. Liedtke C, Mazouni C, Hess KR, et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
8. Jatoi I, Anderson WF, Jeong JH, Redmond CK: Breast cancer adjuvant therapy: Time to consider its time-dependent effects. J Clin Oncol 2011; 29: 2301-2304.
9. von Minckwitz G, Untch M, Blohmer JU, et al.: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
10. Cortazar P, Zhang L, Untch M, et al.: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 2014; 384: 164-172.
11. Heitz F, Harter P, Lueck HJ, et al.: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009; 45: 2792-2798.
12. Lin NU, Claus E, Sohl J, et al.: Sites of distant recurrence and clinical outcomes in patients with metastatic triplenegative breast cancer: High incidence of central nervous system metastases. Cancer 2008; 113: 2638-2645.
13. Cadoo KA, McArdle O, O'Shea AM, et al.: Management of unusual histological types of breast cancer. Oncologist 2012; 17: 1135-1145.
14. Huober J, Gelber S, Goldhirsch A, et al.: Prognosis of medullary breast cancer: Analysis of 13 international breast cancer study group (IBCSG) trials. Ann Oncol 2012; 23: 2843-2851.
15. Lehmann BD, Bauer JA, Chen X, et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
16. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA: New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res 2014; 20: 782-790.
17. Baselga J, Gomez P, Greil R, et al.: Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31: 2586-2592.
18. Carey LA, Rugo HS, Marcom PK, et al.: TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30: 2615-2623.
19. Isakoff SJ, Mayer EL, He L, et al.: TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; [Epub ahead of print].
20. Tutt A, Ellis P, Kilburn L, et al.: Abstract s3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res 2015; 75:S3-01.
21. Byrski T, Dent R, Blecharz P, et al.: Results of a phase II open-label, non randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012; 14:R110.
22. Sikov WM, Berry DA, Perou CM, et al.: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dosedense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triplenegative breast cancer: CALGB 40603 (alliance). J Clin Oncol 2015; 33: 13-21.
23. von Minckwitz G, Schneeweiss A, Loibl S, et al.: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014; 15: 747-756.
24. Von Minckwitz G, Hahnen E, Fasching PA, et al.: Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. ASCO Meeting Abstracts 2014; 32: 1005.
25. Farmer H, McCabe N, Lord CJ, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
26. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819.
27. Tutt A, Robson M, Garber JE, et al.: Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010; 376: 235-244.
28. Audeh MW, Carmichael J, Penson RT, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010; 376: 245-251.
29. Gelmon KA, Tischkowitz M, Mackay H, et al.: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol 2011; 12: 852-861.
30. Rugo H, Olopade O, DeMichele A, et al.: Abstract s5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 trial. Cancer Res 2013; 73:S5-02.
31. Bouwman P, Jonkers J: Molecular pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 2014; 20: 540-547.
32. Andre F, Job B, Dessen P, et al.: Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-451.
33. Linderholm BK, Hellborg H, Johansson U, et al.: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009; 20: 1639-1646.
34. Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
35. Gray R, Bhattacharya S, Bowden C, et al.: Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-4972.
36. Miles DW, Chan A, Dirix LY, et al.: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
37. Pivot X, Schneeweiss A, Verma S, et al.: Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO. Eur J Cancer 2011; 47: 2387-2395.
38. Robert NJ, Dieras V, Glaspy J, et al.: Ribbon-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
39. Rugo HS, Barry WT, Moreno-Aspitia A, et al.: CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2012; 30 Suppl; abstr CRA1002.
40. Lang I, Brodowicz T, Ryvo L, et al.: Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: Interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013; 14: 125-133.
41. Brufsky A, Valero V, Tiangco B, et al.: Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the Ribbon-2 trial. Breast Cancer Res Treat 2012; 133: 1067-1075.
42. Miles DW, Dieras V, Cortes J, et al.: First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24: 2773-2780.
43. Cameron D, Brown J, Dent R, et al.: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 933-942.
44. von Minckwitz G, Eidtmann H, Rezai M, et al.: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
45. Bear HD, Tang G, Rastogi P, et al.: Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-320.
46. Cobleigh MA, Langmuir VK, Sledge GW, et al.: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117-124.
47. Bianchi G, Loibl S, Zamagni C, et al.: Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009; 20: 616-624.
48. Moreno-Aspitia A, Morton RF, Hillman DW, et al.: Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North central cancer treatment group and mayo clinic trial N0336. J Clin Oncol 2009; 27: 11-15.
49. Barrios CH, Liu MC, Lee SC, et al.: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121-131.
50. Taylor SK, Chia S, Dent S, et al.: A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010; 15: 810-818.
51. Robert NJ, Saleh MN, Paul D, et al.: Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92.
52. Bergh J, Bondarenko IM, Lichinitser MR, et al.: Firstline treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. J Clin Oncol 2012; 30: 921-929.
53. Crown JP, Dieras V, Staroslawska E, et al.: Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013; 31: 2870-2878.
54. Schwartzberg LS, Tauer KW, Hermann RC, et al.: Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res 2013; 19: 2745-2754.
55. Nielsen TO, Hsu FD, Jensen K, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
56. Rakha EA, El-Sayed ME, Green AR, et al.: Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
57. Di Leo A, Gomez HL, Aziz Z, et al.: Phase III, doubleblind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26: 5544-5552.
58. Finn RS, Press MF, Dering J, et al.: Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009; 27: 3908-3915.
59. Balko JM, Cook RS, Vaught DB, et al.: Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 2012; 18: 1052-1059.
60. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, et al.: Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106 Suppl 1:S32 abstr 308.
61. Brown SD, Warren RL, Gibb EA, et al.: Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014; 24: 743-750.
62. Nanda R, Chow LQ, Dees EC, et al.: Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res 2015; 75:S1-09.
63. Emens LA, Braiteh FS, Cassier P, et al.: Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res 2015; 75:PD1-6.
64. Yeatman TJ: A renaissance for Src. Nature Rev Cancer 2004; 4: 470-480.
65. Finn RS, Dering J, Ginther C, et al.: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basaltype/' triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326.
66. Huang F, Reeves K, Han X, et al.: Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection. Cancer Res 2007; 67: 2226-2238.
67. Mayer E, Baurain J, Sparano J, et al.: Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. J Clin Oncol 2009; 27 Supp:15s abstr 1011.
68. Marty B, Maire V, Gravier E, et al.: Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008; 10:R101.
69. Ueng SH, Chen SC, Chang YS, et al.: Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int J Clin Exp Pathol 2012; 5: 806-813.
70. Walsh S, Flanagan L, Quinn C, et al.: mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors. Breast 2012; 21: 178-182.
71. Huober J, Fasching PA, Hanusch C, et al.: Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) +/-bevacizumab-Results of the randomised geparquinto study (GBG 44). Eur J Cancer 2013; 49: 2284-2293.
72. Balko JM, Giltnane JM, Wang K, et al.: Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014; 4: 232-245.